Summit Partners Public Asset Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Summit Partners Public Asset Management’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-103,100	Closed	-$1.93M	–	101
2018 Q3	$1.93M	Buy	+103,100	New	+$2.37M	0.13%	84
2017 Q1	–	Sell	-100,000	Closed	-$1.9M	–	106
2016 Q4	$1.9M	Hold	100,000	–	–	0.41%	80
2016 Q3	$1.95M	Buy	+100,000	New	+$1.69M	0.32%	84

Other funds holding FLXN

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Summit Partners Public Asset Management's FLXN Position: Q3 2018 in Review

Summit Partners Public Asset Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2018, closing a stake of 260,000 shares — an estimated $5.97M sold.

Summit Partners Public Asset Management first reported a position in FLXN in Q1 2018 and held it in 2 quarters. The position peaked at $6.72M in Q2 2018. 129 funds tracked by Wall St. Rank hold FLXN as of Q3 2018.

Summit Partners Public Asset Management reported no remaining Flexion Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
Summit Partners Public Asset Management sold 260,000 Flexion Therapeutics, Inc. shares in Q3 2018, an estimated $5.97M.
Summit Partners Public Asset Management first reported a position in Flexion Therapeutics, Inc. in Q1 2018 and held it in 2 quarters.
Summit Partners Public Asset Management's Flexion Therapeutics, Inc. position peaked at $6.72M in Q2 2018.
129 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2018.

Based on Summit Partners Public Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.